#Free BiQ: Updated Outlook (TARS)

The Near/Mid Term Outlook for Tarsus Pharmaceuticals (TARS) has been upgraded from Cautious to Neutral due to the recent pullback in the share price, resulting in a more favorable valuation.

Click here to view the iQ Cheat Sheet for TARS.

Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @_Biotech_iQ.

Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary.